Display options
Cite
Zhang ZC, Fu S, Wang F, et al. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014;7:457-67doi: 10.2147/OTT.S58791.
Zhang, Z. C., Fu, S., Wang, F., Wang, H. Y., Zeng, Y. X., & Shao, J. Y. (2014). Oncogene mutational profile in nasopharyngeal carcinoma. OncoTargets and therapy, 7457-67. https://doi.org/10.2147/OTT.S58791
Zhang, Zi-Chen, et al. "Oncogene mutational profile in nasopharyngeal carcinoma." OncoTargets and therapy vol. 7 (2014): 457-67. doi: https://doi.org/10.2147/OTT.S58791
Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther. 2014 Mar 20;7:457-67. doi: 10.2147/OTT.S58791. eCollection 2014. PMID: 24672248; PMCID: PMC3964172.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2014 Mar 20;7:457-67. doi: 10.2147/OTT.S58791. eCollection 2014.

Oncogene mutational profile in nasopharyngeal carcinoma.

OncoTargets and therapy

Zi-Chen Zhang, Sha Fu, Fang Wang, Hai-Yun Wang, Yi-Xin Zeng, Jian-Yong Shao

Affiliations

  1. Department of Molecular Diagnostics, Guangzhou, People's Republic of China.
  2. Department of Experimental Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, People's Republic of China.

PMID: 24672248 PMCID: PMC3964172 DOI: 10.2147/OTT.S58791

Abstract

Nasopharyngeal carcinoma (NPC) is a common tumor in Southern China, but the oncogene mutational status of NPC patients has not been clarified. Using time-of-flight mass spectrometry, 238 mutation hotspots in 19 oncogenes were examined in 123 NPC patients. The relationships between mutational status and clinical data were assessed with a χ(2) or Fisher's exact test. Survival analysis was performed using the Kaplan-Meier method with the log-rank test. In 123 patients, 21 (17.1%) NPC tumors were positive for mutations in eight oncogenes: six patients had PIK3CA mutations (4.9%), five NRAS mutations (4.1%), four KIT mutations (3.3%), two PDGFRA mutations (1.6%), two ABL mutations (1.6%), and one with simultaneous mutations in HRAS, EGFR, and BRAF (1%). Patients with mutations were more likely to relapse or develop metastasis than those with wild-type alleles (P=0.019). No differences or correlations were found in other clinical characteristics or in patient survival. No mutations were detected in oncogenes AKT1, AKT2, CDK, ERBB2, FGFR1, FGFR3, FLT3, JAK2, KRAS, MET, and RET. These results demonstrate an association between NPC and mutations in NRAS, KIT, PIK3CA, PDGFRA, and ABL, which are associated with patient relapse and metastasis.

Keywords: NPC; mutation; oncogene

References

  1. Pathol Res Pract. 2002;198(2):97-102 - PubMed
  2. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):28-31 - PubMed
  3. Mol Cancer Ther. 2013 Feb;12(2):220-9 - PubMed
  4. Invest New Drugs. 2010 Jun;28(3):326-33 - PubMed
  5. Cell Cycle. 2006 Aug;5(15):1607-11 - PubMed
  6. Cancer Sci. 2009 Nov;100(11):2034-9 - PubMed
  7. Curr Cancer Drug Targets. 2008 Dec;8(8):733-40 - PubMed
  8. Gastroenterology. 2003 Sep;125(3):660-7 - PubMed
  9. Histopathology. 2014 Apr;64(5):722-30 - PubMed
  10. Nat Genet. 2010 Jul;42(7):599-603 - PubMed
  11. Virchows Arch. 2011 Jan;458(1):95-8 - PubMed
  12. Chin J Cancer. 2010 Feb;29(2):131-5 - PubMed
  13. Head Neck. 2003 Oct;25(10):864-72 - PubMed
  14. J Invest Dermatol. 2010 Jan;130(1):314-6 - PubMed
  15. PLoS One. 2009 May 27;4(5):e5717 - PubMed
  16. J Clin Oncol. 2008 Nov 20;26(33):5352-9 - PubMed
  17. J Otolaryngol. 2004 Oct;33(5):304-7 - PubMed
  18. J Clin Oncol. 2005 Feb 20;23(6):1118-24 - PubMed
  19. Med Oncol. 2009;26(3):322-6 - PubMed
  20. Cancer Invest. 2000;18(1):6-10 - PubMed
  21. J Clin Oncol. 2003 Dec 1;21(23):4342-9 - PubMed
  22. Cancer Res. 2004 Mar 15;64(6):1972-4 - PubMed
  23. Semin Cancer Biol. 2012 Apr;22(2):162-5 - PubMed
  24. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Jan;25(2):67-70 - PubMed
  25. Annu Rev Med. 2008;59:429-42 - PubMed
  26. Science. 2003 Jan 31;299(5607):708-10 - PubMed
  27. Breast Cancer Res Treat. 2011 Sep;129(2):373-86 - PubMed
  28. Int J Oncol. 2009 Apr;34(4):1017-27 - PubMed
  29. Zhonghua Bing Li Xue Za Zhi. 2005 Feb;34(2):75-9 - PubMed
  30. J Clin Invest. 2010 Aug;120(8):2655-8 - PubMed
  31. Clin Otolaryngol Allied Sci. 2001 Apr;26(2):82-92 - PubMed
  32. Cancer Genet Cytogenet. 2008 Dec;187(2):74-9 - PubMed
  33. PLoS One. 2013;8(3):e59879 - PubMed
  34. Nature. 1990 Aug 2;346(6283):470-1 - PubMed
  35. Ai Zheng. 2007 Jan;26(1):15-20 - PubMed
  36. BMC Cancer. 2006 Jul 06;6:178 - PubMed
  37. Comp Funct Genomics. 2007;:57513 - PubMed
  38. Adv Otorhinolaryngol. 2011;72:157-9 - PubMed
  39. Cell Mol Biol (Noisy-le-grand). 2010 Dec 15;56 Suppl:OL1442-6 - PubMed
  40. Pharmacogenet Genomics. 2006 Jan;16(1):73-4 - PubMed
  41. J Virol. 2011 Nov;85(21):11291-9 - PubMed
  42. J Clin Oncol. 2012 Feb 1;30(4):433-40 - PubMed
  43. Lab Invest. 2007 Apr;87(4):365-71 - PubMed
  44. J Clin Oncol. 2012 Jan 20;30(3):316-21 - PubMed
  45. Cancer. 2005 Jan 1;103(1):22-31 - PubMed
  46. Int J Oncol. 2002 Mar;20(3):467-73 - PubMed
  47. Genes Cancer. 2011 Mar;2(3):344-58 - PubMed
  48. Lancet. 2005 Jun 11-17;365(9476):2041-54 - PubMed
  49. Chirurgia (Bucur). 2012 Sep-Oct;107(5):640-5 - PubMed

Publication Types